Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | SVP, Head of Development | February 25, 2022 | March 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SANGAMO THERAPEUTICS, INC
Report date February 25, 2022 · Filed March 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 75,537 |
Reported balance
After 2022-02-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-02-25 · Grant · Acquired 41,000 · Balance 75,537 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F2: Includes 26,668 shares subject to the Reporting Person's February 12, 2021 RSU grant that will vest in two remaining annual installments of 13,332 shares and 13,336 shares on February 12, 2023 and 2024, respectively, subject to Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.90 · Expires 2032-02-24 | Direct | 110,700 |
Reported balance
After 2022-02-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-25 · Grant · Acquired 110,700 · Balance 110,700 F3: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
F2: Includes 26,668 shares subject to the Reporting Person's February 12, 2021 RSU grant that will vest in two remaining annual installments of 13,332 shares and 13,336 shares on February 12, 2023 and 2024, respectively, subject to Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
F3: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2022 Filed Mar 1, 2022 22:20 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 110,700 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001209191-22-014176 · doc4.xml · derivative · entry 2 Schott Robert J. · CIK 0001845310 · SVP, Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,700 Underlying: Common Stock · 110,700 shares Expires 2032-02-24 F3 · derivative.exercise_date: One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:20 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 41,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014176 · doc4.xml · nonDerivative · entry 1 Schott Robert J. · CIK 0001845310 · SVP, Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,537 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. F2 · balance_after: Includes 26,668 shares subject to the Reporting Person's February 12, 2021 RSU grant that will vest in two remaining annual installments of 13,332 shares and 13,336 shares on February 12, 2023 and 2024, respectively, subject to Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 12, 2022 Filed Feb 24, 2022 22:32 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Tax withholdingCommon Stock | 5,463 | $5.76 | $31,466.88 |
DisclosureSEC source: 0001209191-22-012765 · doc4.xml · nonDerivative · entry 1 Schott Robert J. · CIK 0001845310 · SVP, Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,537 F1 · shares: Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on February 12, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on February 11, 2022 of $5.76/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). F2 · balance_after: Includes 7,869 shares resulting from the February 12, 2022 vesting of the Reporting Person's February 12, 2021 RSU grant and 26,668 shares subject to such RSU grant that will vest in two remaining annual installments of 13,332 shares and 13,336 shares on February 12, 2023 and 2024, respectively. The vesting of all such RSUs is subject to the Reporting Person's continuous service as defined in the Issuer's 2018 EIP through such dates and subject to acceleration as defined in the 2018 EIP. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 23:21 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $13.68 | $0.00 |
DisclosureSEC source: 0001209191-21-010954 · doc4.xml · derivative · entry 2 Schott Robert J. · CIK 0001845310 · SVP, Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-02-11 F2 · derivative.exercise_date: One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of Continuous Service, as defined in the 2018 EIP, as amended, by the Reporting Person measured from the February 12, 2021 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through each such vesting date, and subject to acceleration as provided in the 2018 EIP, as amended. Remarks: Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 23:21 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010954 · doc4.xml · nonDerivative · entry 1 Schott Robert J. · CIK 0001845310 · SVP, Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · shares: Includes 40,000 shares of common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person on February 12, 2021. The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.